Pharmacy Board Looks to Shape Future of Pharmaceutical Practice

Over the years, Kenya has made notable strides in improving access to medicines and healthcare services, but ensuring that every patient receives safe, effective and quality-assured medicines has remained a critical challenge.

To address these concerns, the Pharmacy and Poisons Board (PPB) is implementing a series of institutional reforms aimed at modernising pharmaceutical regulation and strengthening patient safety across the country.

The reforms are expected to enhance the regulation of medicines, improve compliance within the pharmaceutical sector and position Kenya as a regional leader in pharmaceutical governance. 

The renewed focus on pharmaceutical reforms was outlined by Pharmacy and Poisons Board Chairperson Dr. John Munyu during the 22nd Kenya Pharmaceutical Association Scientific Conference held in Mombasa.

The conference brought together pharmacists, pharmaceutical technologists, regulators, manufacturers, academia, development partners and policymakers to discuss the future of pharmaceutical practice in Kenya.

“Every Kenyan deserves medicine that is safe, effective and of assured quality dispensed by qualified professionals operating within a credible and responsive regulatory system,“ he said as per The Star.

Dr. Munyu urged pharmacists, pharmaceutical technologists and proprietors to embrace ethical practice and regulatory compliance, saying the future of pharmaceutical practice depends on strong collaboration between regulators and healthcare professionals. 

The conference, officially opened by Principal Secretary for Public Health and Professional Standards Mary Muthoni, was held under the theme, “Optimising Pharmaceutical Practice to Advance Patient Safety, Medicine Access and Healthcare Excellence.”

Participants explored ways of improving medicine access while strengthening the systems that safeguard public health.

According to Dr. Munyu, the Pharmacy and Poisons Board is undergoing significant institutional reforms designed to transform it into a modern, efficient and internationally recognised National Medicines Regulatory Authority capable of responding to evolving healthcare needs.

“The Board is implementing institutional reforms to position PPB as a modern, efficient and internationally recognised National Medicines Regulatory Authority capable of responding to emerging health challenges while facilitating innovation and access to quality-assured medical products.”

He explained that the reforms are intended to establish a transparent, predictable and risk-based regulatory environment that promotes ethical professional practice while enhancing public confidence in Kenya’s pharmaceutical system.

A stronger regulatory framework, he said, will also create a more attractive environment for investment in the country’s pharmaceutical sector by providing greater certainty for manufacturers, distributors and healthcare providers.

Enhancing Patient Safety

Patient safety remains at the centre of the Pharmacy and Poisons Board’s reform agenda. The Board believes that stronger oversight and compliance will significantly reduce risks associated with poor-quality medicines, counterfeit products and weak distribution systems.

The demand for healthcare services continues to rise hence maintaining strict standards across the pharmaceutical supply chain has become increasingly important. Industry experts say medicines can only achieve their intended therapeutic benefits when their quality, safety and effectiveness are preserved from production to the point of use.

Dr. Munyu challenged pharmaceutical professionals to strengthen compliance with Good Storage and Distribution Practice (GSDP) standards, noting that proper handling of medicines is a shared responsibility across the healthcare sector.

“Preserving the quality, safety and efficacy of medicines throughout the supply chain is a professional obligation that directly affects patient outcomes.”

The emphasis on Good Storage and Distribution Practice reflects growing recognition that medicine quality can be compromised if products are improperly transported or stored before reaching patients. Strengthening compliance is therefore expected to improve treatment outcomes while reducing losses associated with damaged or substandard medicines.

Building a Modern Regulatory Authority

The institutional reforms are also expected to improve the efficiency of the Pharmacy and Poisons Board by strengthening its ability to regulate emerging pharmaceutical products and respond to changing healthcare challenges.

With advances in pharmaceutical research, biotechnology and digital health, regulators are increasingly required to adapt to new technologies while maintaining rigorous standards for medicine approval and post-market surveillance.

The Board’s transformation into an internationally recognised National Medicines Regulatory Authority is expected to align Kenya with global best practices, improving the country’s standing within regional and international healthcare systems.

Stakeholders attending the conference observed that a modern regulatory authority is essential for encouraging pharmaceutical innovation while protecting consumers from unsafe or ineffective medical products.

Collaboration Key to Success

Participants at the conference agreed that the success of the reforms will depend on sustained collaboration between government institutions, healthcare professionals, manufacturers, academia and development partners.

Such partnerships are expected to strengthen professional standards, encourage continuous learning and improve regulatory compliance throughout the pharmaceutical sector.

Industry leaders also noted that ethical practice remains fundamental to maintaining public trust in healthcare institutions. 

The initiatives are expected to strengthen healthcare delivery while contributing to the country’s broader efforts to achieve universal health coverage.